XenoGesis, a UK-based specialist in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation, has purchased of a state-of-the-art LC-MS/MS machine.
The company currently has two mass spectrometry machines at its BioCity base in Nottingham.
The Waters Xevo TQ-S micro with Acquity I-class, to be installed in August, will increase capacity by around 50%, as well as adding a new range of capabilities and potentially broadening the number of clients and types of projects that can be supported.
XenoGesis' Managing Director Richard Weaver said: 'This is a significant move for us. Bringing in this new technology enhances our capabilities and increases our capacity. Having the new LC-MS/MS machine in place will help to differentiate us further.'
The new equipment comes at a time when XenoGesis has announced record growth, with turnover exceeding £1m in just over three years.
The investment made by XenoGesis in the LC-MS/MS machine has been supported by a grant from the Invest to Grow scheme managed by the University of Derby, which has provided just under a third of the funds needed.
David Harper, the University’s Head of Strategic Programmes said: 'We are delighted to support the growth plans of XenoGesis. The funding will allow the company to invest in important capital equipment, and will lead directly to the creation of high quality jobs.'
The Invest to Grow programme is designed to support established private sector businesses to innovate, grow and create jobs, and comprises Regional Growth Fund monies of £16m.
